🪔Sculpture Exhibition The sculpture is distinctFor lunch, I eat at a beachside restaurant, ordering grilled fish and a salad, the fish fresh and flavorful, caught that morning, and I sip a cold glass of sangria, savoring the moment of relaxation.
🌉Orange with sugar, vanilla and lemonCut off emotional attachment to old bad habits stalling your growth. Breaking old patterns feels uncomfortable temporarily, yet long-term self-improvement rewards outweigh short-term discomfort.
🍼German Learned phrasesDon’t let fleeting sadness dim your inner light. Collect small warm moments: hot coffee, soft moonlight, strangers’ kind smiles, these trivial fragments will slowly heal every tired part of your soul.
Know that you are cherished deeply and genuinely. The elevator doors shut, and I rest against the wall, shutting my eyes briefly. The elevator's hum is calming, and I inhale deeply, getting myself ready for the day ahead.
Aus der Feder eines ehemaligen linken Aktivisten: Satirische Geschichten aus der Woke-Welt in 'Der Schwurbelpeter' – in Reimform und mit Ironie-Alarm! Kommt euch die Moralkeule bekannt vor? Hier eine Kostprobe als Video mit dem Triggerthema: Klimawandel
@zipjet@pjhermaninmaine Just curious. Why did you wait for so long time to sell $FGEN at all time low? They are pretty much undervalued/oversold right now...still having roxa in rest of the world and pipeline with pam in PH3?!
LR $FGEN Even in bear-case scenario of no US/EU approval for roxa (which is unlikely),believe $FGEN worth $52/share, but
if roxa does secure approval in both DD &non-dialysis-dependent (NDD) patients,stock is worth $85. positive view of pamrevlumab, which justifies $30/share
@marko1332@sentivcapital This is the last desperate attempt by shorts to cover their positions prior to $FGEN approval. And by big pharma to avoid $FGEN market entry. It’s time to involve @WSBChairman and @wallstreetbets? LOL
@KatzungMD@tuduylinh@bradloncar Azn is willing to take just roxadustat, imo. Pamrevlumab fits perfectly in the portfolio of Roche. Thinking about a spin off of $FGEN in 2021?!
Roxadustat Superior to Epoetin Alfa in Patients With Anemia and Dialysis-Dependent Chronic Kidney Disease - ASH Clinical News In patients with anemia and dialysis:treatment with roxadustat led to higher Hb levels and a reduced need for PRBC X/w rx with epo https://t.co/0L7ailCpuX
This chart shows how eight key strengths – education, innovation and technology, competitiveness, military, trade, output, financial center, and reserve status – typically determine a country’s rise and decline, and how they typically evolve. (1/2)